Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01CCT
|
|||
| Drug Name |
Triazole derivative 1
|
|||
| Synonyms |
PMID26560530-Compound-42
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Universit de Montral
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H13N5O5
|
|||
| Canonical SMILES |
C1=CC(=CC=C1CN2C=C(N=N2)C(=O)C=CC3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-]
|
|||
| InChI |
1S/C18H13N5O5/c24-18(10-5-13-1-6-15(7-2-13)22(25)26)17-12-21(20-19-17)11-14-3-8-16(9-4-14)23(27)28/h1-10,12H,11H2/b10-5+
|
|||
| InChIKey |
CVKOJPBBOPIMAL-BJMVGYQFSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.